Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : DAVI Farmaceutica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa And DÁVI License Clobetasol for Post-Operative Pain Therapy
Details : Under the term license agreement, DAVI will gain the exclusive rights to commercialize APP13007 (clobetasol propionate) for the treatment of inflammation and pain following ocular surgery.
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 31, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : DAVI Farmaceutica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Alliance Global Partners
Deal Size : Undisclosed
Deal Type : Public Offering
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
Details : The Company intends to use the net proceeds to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study.
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 27, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Alliance Global Partners
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eyenovia Launches Clobetasol Propionate Suspension for Post-Ocular Surgery Pain
Details : APP13007 (clobetasol propionate) ophthalmic suspension 0.05% is approved by the FDA for the treatment of post-operative inflammation and pain following ocular surgery.
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Dawson James Securities
Deal Size : $5.1 million
Deal Type : Public Offering
Eyenovia Announces Closing of Public Offering
Details : The Company will fund commercialization activities for Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) and clobetasol propionate, complete the pediatric myopia clinical study.
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 23, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Dawson James Securities
Deal Size : $5.1 million
Deal Type : Public Offering
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Dawson James Securities
Deal Size : $5.1 million
Deal Type : Public Offering
Eyenovia Announces Pricing of $5.14 Million Public Offering
Details : The Company will fund commercialization activities for Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) and clobetasol propionate, complete the pediatric myopia clinical study.
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 21, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Dawson James Securities
Deal Size : $5.1 million
Deal Type : Public Offering
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Dawson James Securities
Deal Size : Undisclosed
Deal Type : Public Offering
Eyenovia, Inc. Announces Proposed Public Offering
Details : The Company will fund commercialization activities for Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) and clobetasol propionate, complete the pediatric myopia clinical study.
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 20, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Dawson James Securities
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Eyenovia
Deal Size : Not Applicable
Deal Type : Not Applicable
Formosa and Eyenovia Begin Co-Development of Clobetasol for Acute Dry Eye Disease
Details : APP13007 (clobetasol propionate) is a nanoparticle ophthalmic formulation of a steroid. It is approved for the treatment of dry eye disease.
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 07, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Eyenovia
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa Pharmaceuticals Announce Licensing Agreement with Apotex for Clobetasol Propionate
Details : Through the licensing agreement, Apotex will gain exclusive rights of APP13007 (clobetasol propionatei) in Canada for commercialization to treat inflammation and pain following ocular surgery.
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 05, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Tabuk Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk for Clobetasol
Details : Tabuk gains rights to APP13007 (clobetasol propionate) for post-ocular surgery pain and inflammation in the MENA region.
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 09, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Tabuk Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Eyenovia
Deal Size : Undisclosed
Deal Type : Agreement
NovaBay and Eyenovia to Co-Promote Ophthalmic Products to U.S. Eyecare Pros
Details : NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension, a steroid for inflammation and pain after ocular surgery, via U.S. physician-dispensed channels.
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 13, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Eyenovia
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?